Design Therapeutics, Inc.
DSGN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$10.24
KIRA · Stoqly’s AI analyst, in plain words
- Design Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
- Design Therapeutics, Inc. lost $69.8M in fiscal 2025.
- Free cash flow was −$54.6M in fiscal 2025, — of revenue.
Market cap
$640M
P/E
—
Revenue
$0.0M
Net income
−$69.8M
Free cash flow
−$54.6M
Operating margin
—
Design Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$69.8M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Design Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- Design Therapeutics, Inc.
- CIK
- 0001807120
Design Therapeutics, Inc. · DSGN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $0.0M | $0.0M |
| Net income | −$35.5M | −$63.3M | −$66.9M | −$49.6M | −$69.8M |
| Diluted EPS | −$0.77 | −$1.14 | −$1.19 | −$0.88 | −$1.22 |
| Cash | |||||
| Cash from operations | −$29.4M | −$51.3M | −$58.6M | −$43.1M | −$54.4M |
| Capital expenditure | $1.5M | $0.9M | $0.3M | $0.3M | $0.2M |
| Free cash flow | −$30.9M | −$52.2M | −$58.8M | −$43.4M | −$54.6M |
| Share count change | 190.8% | 21.3% | 0.5% | 1.1% | 1.3% |
| Debt and strength | |||||
| Cash and short-term investments | $384M | $330M | $282M | $245M | $220M |
| Shareholders' equity | $382M | $327M | $278M | $242M | $213M |
| Current ratio | 73.0x | 31.1x | 29.6x | 29.3x | 17.1x |
| Returns and quality | |||||
| Return on equity | −19.2% | −17.8% | −22.1% | −19.1% | −30.7% |
| Return on tangible equity | −9.3% | −19.3% | −24.1% | −20.5% | −32.8% |
| Piotroski F-score | — | — | — | — | 1 |
| Altman Z'' | 53.0 | 28.7 | 26.8 | 27.1 | 15.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Design Therapeutics, Inc. · DSGN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.24 a share, the company is worth $640M.
Source: SEC EDGAR XBRL filings (CIK 0001807120). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.